Abstract

Increased donated and subsidised medicines for malaria are saving countless lives in Africa, but there is probably increasing theft and diversion of those medicines. The impact of medicine diversion is unknown but potentially dangerous and may bolster criminal networks and increase medicine stock outs (1,2). This study demonstrates...

The private sector can and should play an important role in public health, but it remains to be seen whether or not the benefits that have arisen from the AMFm could have been achieved through alternative mechanisms and potentially at lower cost.

The malaria community has done a great job over the past decade to combat the disease. But this may be about to change.

Leadership is a wonderful thing, but it is truly found when it is tested, and on that count malaria leadership has failed.

There are always costs of both action and inaction; however, before a costly scheme is funded, better evidence of its effectiveness should be established.

A new global subsidy to give malaria patients the best treatment may divert money from simpler campaigns and could undermine drug quality.

The Global Fund is to be commended for its transparency, but it has failed to act on the information it has gleaned, and continues to allow its funds to be used by governmental distribution systems known to be corrupt.

Drugs donated to developing countries are being stolen by criminal groups, which harms patients, encourages criminal networks, and probably leads to dangerous counterfeiting.